The Global Arthritis Therapy Partnering Terms and Agreements since 2010 report provides understanding and access to partnering deals and agreements entered into by the world's leading healthcare companies.
The report provides an analysis of partnering deals. The majority of deals are discovery or development stage whereby the licensee obtains a right or an option right to license the licensors technology. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes.
The initial chapters of this report provide an orientation of partnering trends.
1 provides an overview of the trends in partnering since 2010, including a summary of deals by industry sector, stage of development, deal type, and technology type.
2 provides a review of the top 10 most active companies in the therapy area, including a comprehensive listing of the deals announced by each company.
3 provides a comprehensive directory of partnering deals signed and announced since 2010. The chapter is organized by company A-Z, stage of development at signing, deal type (collaborative R&D, co-promotion, licensing etc), and technology type. Each deal title links via Weblink to an online version of the deal record, and where available the contract document, providing easy access to each contract document on demand.
4 provides a listing of partnering deals where a contract document is available alongside the deal record.
5 and 6 provide a summary of M&A deals since 2010 where the acquired company is active in the therapy area of interest.
7 and 8 provide a summary of financings since 2010 where the financed company is active in the therapy area of interest.
Global Therapy Partnering Terms and Agreements since 2010 report provides the reader with the following key benefits:
- In-depth understanding of deal trends since 2010
- Access to headline, upfront, milestone and royalty data
- Comprehensive access to multiple deals entered into by the world's biopharma companies since 2010
- Insight into key deal terms included in contracts, where disclosed
- Understand the key deal terms companies have agreed in deals
- Undertake due diligence to assess suitability of your proposed deal terms for partner companies
- Aspen Pharmacare
- Baxter International
- Biogen Idec
- Boehringer Ingelheim
- Bristol-Myers Squibb
- Daiichi Sankyo
- Dainippon Sumitomo
- Eli Lilly
- Endo Pharmaceuticals
- Forest Laboratories
- Gilead Sciences
- Johnson & Johnson
- Merck & Co
- Merck KGaA
- Mitsubishi Tanabe
- Novo Nordisk
- Warner Chilcott
For more information about this report visit http://www.researchandmarkets.com/research/xj9n7n/global_arthritis
Laura Wood, Senior Manager
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/global-arthritis-partnering-2010-2016-understanding-and-access-to-partnering-deals-and-agreements-entered-into-by-the-worlds-leading-healthcare-companies---research-and-markets-300375882.html
SOURCE Research and Markets